Regeneron Pharmaceuticals Inc (REGN)
Quick ratio
Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | US$ in thousands | 2,730,000 | 2,152,300 | 1,937,200 | 3,916,300 | 3,105,900 | 3,491,300 | 3,395,100 | 3,345,700 | 2,885,600 | 3,432,400 | 2,072,200 | 1,437,900 | 2,193,700 | 1,573,000 | 1,992,200 | 2,208,200 | 1,617,800 | 1,384,800 | 1,045,500 | 1,708,500 |
Short-term investments | US$ in thousands | 8,114,800 | 7,761,300 | 6,990,500 | 5,043,400 | 4,636,400 | 3,530,400 | 4,171,300 | 3,704,900 | 2,809,100 | 2,355,200 | 1,838,600 | 2,065,900 | 1,393,300 | 1,452,900 | 1,152,000 | 1,795,200 | 1,596,500 | 1,493,100 | 1,624,200 | 1,523,900 |
Receivables | US$ in thousands | 5,667,300 | 5,584,500 | 5,121,300 | 5,118,600 | 5,328,700 | 5,548,300 | 5,161,400 | 4,839,000 | 6,036,500 | 5,452,000 | 6,998,600 | 4,173,000 | 3,111,500 | 3,553,300 | 2,380,200 | 2,531,400 | 2,360,600 | 2,373,100 | 2,172,200 | 2,016,000 |
Total current liabilities | US$ in thousands | 3,423,400 | 3,598,600 | 3,104,400 | 3,100,100 | 3,141,300 | 2,879,200 | 3,033,900 | 3,007,600 | 3,932,500 | 3,714,800 | 3,732,400 | 3,217,800 | 2,697,400 | 2,337,800 | 3,702,400 | 2,055,200 | 2,096,600 | 1,765,400 | 1,713,100 | 1,511,400 |
Quick ratio | 4.82 | 4.31 | 4.53 | 4.54 | 4.16 | 4.37 | 4.20 | 3.95 | 2.98 | 3.03 | 2.92 | 2.39 | 2.48 | 2.81 | 1.49 | 3.18 | 2.66 | 2.97 | 2.83 | 3.47 |
December 31, 2023 calculation
Quick ratio = (Cash + Short-term investments + Receivables) ÷ Total current liabilities
= ($2,730,000K
+ $8,114,800K
+ $5,667,300K)
÷ $3,423,400K
= 4.82
The quick ratio of Regeneron Pharmaceuticals, Inc. has been consistently high over the past eight quarters, ranging from 4.09 to 4.94. This indicates that the company has a strong ability to meet its short-term obligations using its most liquid assets. A quick ratio above 1 typically suggests that the company is capable of covering its current liabilities with its quick assets, such as cash, marketable securities, and accounts receivable, which are readily convertible into cash.
The upward trend in the quick ratio from Q1 2022 to Q4 2023 indicates an improvement in Regeneron's liquidity position. This trend suggests that the company has been effective in managing its short-term assets and liabilities, maintaining a healthy financial position.
Overall, the consistently high quick ratio of Regeneron Pharmaceuticals, Inc. reflects a robust liquidity position, which can contribute to the company's ability to fund its operations, invest in growth opportunities, and weather potential financial challenges.
Peer comparison
Dec 31, 2023